Ensysce Biosciences Inc (ENSC) Stock Price, Quote & News

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4196

Website: www.ensysce.com

Address:

7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

StockDreamin Apr. 25 at 4:37 AM

$ENSC they must have diluted...it doesnt even wander off the low 40s now

0 · Reply

StockDreamin Apr. 24 at 8:19 PM

$ENSC crapola

0 · Reply

Sunnybhargava Apr. 24 at 4:23 PM

$ENSC you can get same price of share what insiders buying before the big news. Now.

0 · Reply

mrsparex Apr. 24 at 3:15 PM

$ENSC Anyone wanting to average down may consider placing a buy order at 40. They tried yesterday but failed. Available SS's dropped 50,000 this morning. Also (if you're "long") keep a high sell order. Once insiders secure their stock... this may fly.

0 · Reply

mrsparex Apr. 24 at 3:07 PM

$ENSC Shorts are paying around 69% They need this to drop below 40 so they can trigger stop losses

0 · Reply

BULLISH1975 Apr. 24 at 2:35 PM

$ENSC i think insiders know rerate- big rerate is coming! insiders wanted huge incentive shares in 2026!!! Do they want SP low this year until they get their cheap shares- probably??? Will interim be great- IMO Yes- could SP finally rerate hard- I hope so ! Is Mgt looking to do deal or partnership- IMO yes… I an holding- If SP falls, I will be looking to add more! no guarantees BUt I think ENSC will run hard in the next 12 months but when???? dyor

0 · Reply

Sunnybhargava Apr. 24 at 2:18 PM

$ENSC added more. This price is a gift. 🎁 once news come this will be 🚀

0 · Reply

StockDreamin Apr. 24 at 1:57 PM

$ENSC i take their posts on here with a grain of salt....been in too many bios that would feed all kind of hopeful updates but end up in bankruptcy

0 · Reply

Kesiya Apr. 24 at 6:08 AM

$ENSC Buy zone!

0 · Reply

Sunnybhargava Apr. 24 at 4:58 AM

$ENSC Are we getting some good news soon😄🚀

0 · Reply

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Apr 7, 2026, 8:00 AM EDT - 18 days ago

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

Mar 30, 2026, 4:50 PM EDT - 26 days ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 8:45 AM EST - 7 weeks ago

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Mar 3, 2026, 8:00 AM EST - 7 weeks ago

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

Feb 27, 2026, 12:10 PM EST - 2 months ago

Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review

Feb 25, 2026, 8:00 AM EST - 2 months ago

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

Feb 23, 2026, 8:00 AM EST - 2 months ago

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

Jan 28, 2026, 8:00 AM EST - 3 months ago

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Jan 21, 2026, 8:00 AM EST - 3 months ago

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Jan 8, 2026, 8:00 AM EST - 3 months ago

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Jan 7, 2026, 12:00 PM EST - 3 months ago

Ensysce Biosciences Transcript: AGM 2025

Jan 5, 2026, 8:00 AM EST - 3 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

Dec 12, 2025, 8:00 AM EST - 4 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Dec 9, 2025, 8:00 AM EST - 4 months ago

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Dec 2, 2025, 8:00 AM EST - 5 months ago

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Nov 20, 2025, 8:00 AM EST - 5 months ago

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Nov 17, 2025, 8:05 AM EST - 5 months ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 14, 2025, 4:15 PM EST - 5 months ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Oct 10, 2025, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Aug 19, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 13, 2025, 4:15 PM EDT - 9 months ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Jul 31, 2025, 8:00 AM EDT - 9 months ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 16, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jun 24, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 11, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 4, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

May 13, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 5:11 PM EDT - 1 year ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Apr 23, 2025, 4:41 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 10, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 9:43 AM EST - 1 year ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Jan 22, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 10, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 4, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 3, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Nov 26, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 12, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Mar 21, 2024, 11:00 AM EDT - 2 years ago

Ensysce Biosciences Earnings Call Transcript: Q4 2023

StockDreamin Apr. 25 at 4:37 AM

$ENSC they must have diluted...it doesnt even wander off the low 40s now

0 · Reply

StockDreamin Apr. 24 at 8:19 PM

$ENSC crapola

0 · Reply

Sunnybhargava Apr. 24 at 4:23 PM

$ENSC you can get same price of share what insiders buying before the big news. Now.

0 · Reply

mrsparex Apr. 24 at 3:15 PM

0 · Reply

mrsparex Apr. 24 at 3:07 PM

$ENSC Shorts are paying around 69% They need this to drop below 40 so they can trigger stop losses

0 · Reply

BULLISH1975 Apr. 24 at 2:35 PM

0 · Reply

Sunnybhargava Apr. 24 at 2:18 PM

$ENSC added more. This price is a gift. 🎁 once news come this will be 🚀

0 · Reply

StockDreamin Apr. 24 at 1:57 PM

$ENSC i take their posts on here with a grain of salt....been in too many bios that would feed all kind of hopeful updates but end up in bankruptcy

0 · Reply

Kesiya Apr. 24 at 6:08 AM

$ENSC Buy zone!

0 · Reply

Sunnybhargava Apr. 24 at 4:58 AM

$ENSC Are we getting some good news soon😄🚀

0 · Reply

Sunnybhargava Apr. 23 at 3:38 PM

$ENSC please update the dates expecting for interim results

1 · Reply

Sunnybhargava Apr. 23 at 3:37 PM

$ENSC

0 · Reply

StockDreamin Apr. 23 at 1:56 PM

$ENSC looks like we're heading to the 30s

0 · Reply

EnsysceBiosciences Apr. 23 at 1:47 PM

$ENSC Opioid overdose remains a major healthcare issue, with nearly 80,000 deaths annually in the U.S. A significant portion involves prescription opioids, often tied to patients taking more than prescribed. This leaves a clear gap between effective pain treatment and safety. We are targeting that gap with PF614-MPAR, designed to maintain therapeutic effect while limiting opioid exposure in overdose scenarios. This approach is supported by our clinical data and directly addresses one of the most common drivers of overdose: Taking too much medication. If this model holds through late-stage development, it could influence prescribing patterns and payer decisions as safety becomes a central factor.

0 · Reply

StockDreamin Apr. 23 at 3:28 AM

$ENSC

1 · Reply

cloverT Apr. 23 at 12:39 AM

$ENSC we are completly screwed! No hope at this point of getting to over $1 before August. We need news on a possible partnership soon!

1 · Reply

StockDreamin Apr. 22 at 11:59 PM

$ENSC it appears there are some crybabies and people on twits that shouldnt be allowed out in the real world because they are triggered, offended, not safe, etc...cant handle my colorful posts and have to report them, which are not aimed at anyone. Now Im getting warnings from stocktwits for stupid things....please cancel your account if you cant handle the real world.

1 · Reply

fromtheothersid3 Apr. 22 at 7:19 PM

$ENSC fintel is for me the most accurat page when it comes to on date info So thats what i see Again and again... As soon , and yes, IF ( WE are still in the USA sharkpool of a stockmarket) WE squeeeezeee, WE should squeeeezeee wild imho ☺️❤️

1 · Reply

BULLISH1975 Apr. 22 at 7:12 PM

$ENSC still holding but wish we had a different CEO! Our CEO is a brilliant Scientist!!! dyor if I had free cash I would add as I like buying the fear and lack if intern news.

0 · Reply

Sunnybhargava Apr. 22 at 7:05 PM

$ENSC

0 · Reply

fromtheothersid3 Apr. 22 at 6:57 PM

$ENSC maybe Management does let the market, be the Market as they are confident, that they are in the right path... This is Just my Personal opinion. In the long therm chart it seems like WE found bottom Bios do need a loong time do have success... Multiple offerings, multiple splits... Imho, as i see the News, No more crazy (some) dilution as they, as other bios, do... They keep the sharestructure tight (indeed with some normal benefit for some, as it Always is) wich is good for US... Imho, this is the time... Maybe Not, but my trust ist high Thats it, thats all Just my two cents ☺️ ❤️

1 · Reply

Sunnybhargava Apr. 22 at 6:51 PM

$ENSC adding at every dip. This is 24 k Gold stock

0 · Reply

Market Cap	3.93M
Revenue (ttm)	5.07M
Net Income (ttm)	-10.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-200.79%
Debt to Equity Ratio	0.00

Volume	261,600
Avg Vol	7,267,114
Day's Range	N/A - N/A
Shares Out	9.28M
Stochastic %K	7%
Beta	1.12
Analysts	Strong Buy
Price Target	$16.45